Securities code: 688488 securities abbreviation: Jiangsu Aidea Pharmaceutical Co.Ltd(688488) Announcement No.: 2022-003
Jiangsu Aidea Pharmaceutical Co.Ltd(688488)
Suggestive announcement on changes in shareholders’ equity
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal liabilities for the authenticity, accuracy and integrity of its contents according to law.
Important content tips:
This equity change belongs to the reduction of shareholders’ holdings, does not involve the tender offer and does not involve the source of funds;
After this equity change, the information disclosure obligor Shanghai LeYang Kairui enterprise management partnership (limited partnership) (hereinafter referred to as “LeYang Kairui”) holds Jiangsu Aidea Pharmaceutical Co.Ltd(688488) (hereinafter referred to as ” Jiangsu Aidea Pharmaceutical Co.Ltd(688488) ” or “the company”) 2099958 shares, accounting for 4.999990% of the total share capital of the company. LeYang Kairui is no longer a shareholder holding more than 5% of the company;
This equity change will not change the controlling shareholder and actual controller of the company.
On January 11, 2022, the company received the simplified report on changes in equity from Le Yang Kairui, and now announces the changes in equity as follows:
1、 Changes in equity this time
(I) information disclosure obligor
Company name: Shanghai LeYang Kairui enterprise management partnership (limited partnership)
Unified social credit code 91321000ma1mu912xf
Registered address: room a1193, building 3, No. 112-118, Gaoyi Road, Baoshan District, Shanghai
The registered capital is 62.32 million yuan
Executive partner Wang Guangrong
Date of establishment: September 12, 2016
Enterprise type: limited partnership
Business scope: general items: enterprise management; Enterprise management consulting; Information consulting service (excluding license)
Information consulting services). (except for the items that need to be approved according to law, they shall be approved according to law with their business license
Main business activities)
Business term: September 12, 2016 to September 7, 2036
Mailing address: room a1193, building 3, No. 112-118, Gaoyi Road, Baoshan District, Shanghai
(II) changes in equity
Shareholder name reduction method reduction time reduction type of shares reduction number of shares reduction proportion
Class (share) (%)
Shanghai leyankai December 2021
Rui enterprise management centralized bidding, March 23 – RMB 2632602 0.626810
Partnership (with block transactions) January 2022 shares
Limited partnership) 11 days
(III) Shareholding before and after changes in shareholders’ equity
Shares held before this equity change name of shareholders holding shares after this equity change number of shares (shares) in total share capital proportion of shares in total share capital (%) (shares) (%)
Shanghai LeYang Kairui Enterprise Management Co., Ltd
Outstanding shares of partnership enterprise 23632560 5.626800 2099958 4.999990
(limited joint stock)
(partner)
2、 Follow up matters involved
1. This equity change is a reduction, which does not involve the tender offer and the source of funds;
2. This equity change is the reduction of shares held by more than 5% of non largest shareholders, which will not lead to changes in the controlling shareholder and actual controller of the company, and will not have an impact on the corporate governance structure and sustainable operation;
3. For the above-mentioned changes in shareholders’ equity, a simplified report on changes in shareholders’ equity has been prepared in accordance with the regulations. For details, the company posted it on the website of Shanghai Stock Exchange (www.sse. Com. CN) on the same day The Jiangsu Aidea Pharmaceutical Co.Ltd(688488) simplified equity change report disclosed;
4. After this equity change, the information disclosure obligor is no longer the shareholder holding more than 5% of the company’s shares, and the reduction plan of the information disclosure obligor has not been completed. The company will urge it to strictly implement the relevant provisions on reduction, and timely disclose relevant information to investors. Please pay attention to investment risks.
It is hereby announced.
Jiangsu Aidea Pharmaceutical Co.Ltd(688488) board of directors January 12, 2022
